Eva Baecklund

Uppsala University — Sweden

Medicine · Health Sciences

41h-index7.8kcitations139works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(57), Lymphoma Diagnosis and Treatment(49), Chronic Lymphocytic Leukemia Research(42), Systemic Lupus Erythematosus Research(32), Salivary Gland Disorders and Functions(18)

Publications139 total

Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland
Annals of the Rheumatic Diseases·2025· 2 citedOpen Access
Diffuse large B cell lymphoma in rheumatoid arthritis patients is associated with elevated B-cell driving factors including CXCL13
Clinical Immunology·2025· 4 citedOpen Access
A high polygenic risk score is associated with SSA/SSB antibody positivity and early onset in primary Sjögren’s disease
Lara D. Veeken·2024· 5 citedOpen Access
Unraveling the Genetics of Shared Clinical and Serological Manifestations in Patients With Systemic Inflammatory Autoimmune Diseases
Arthritis & Rheumatology·2024· 6 citedOpen Access
OP0113 GENOME-WIDE ASSOCIATION STUDY OF Ro/SSA+ AND Ro/SSA-SJÖGREN’S CASES IN THE SJÖGREN’S GENETIC NETWORK (SGENE) DEMONSTRATES DIVERGENT GENETIC ARCHITECTURE IN PATIENT SUBPHENOTYPES
Annals of the Rheumatic Diseases·2024
OP0141 EXPLORING REGULATORY DYNAMICS: FUNCTIONAL SNPS IN THE PRDM1-ATG5 LOCUS IMPLICATED IN SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN’S DISEASE
Annals of the Rheumatic Diseases·2024
Variants in the <i>DDX6-CXCR5</i> autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland
2023· 1 citedOpen Access
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
Annals of the Rheumatic Diseases·2023· 44 citedOpen Access
Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis
Lara D. Veeken·2023· 6 citedOpen Access
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
Annals of the Rheumatic Diseases·2023· 83 citedOpen Access
Author Correction: Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells
Nature Communications·2023· 3 citedOpen Access
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a <i>post hoc</i> analysis of ORAL Surveillance
Therapeutic Advances in Musculoskeletal Disease·2023· 19 citedOpen Access
Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
RMD Open·2022· 3 citedOpen Access
Author Correction: Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells
Nature Communications·2022· 7 citedOpen Access
Genome-Wide Association Study of Liver Enzyme Elevation in an Extended Cohort of Rheumatoid Arthritis Patients Starting Low-Dose Methotrexate
Pharmacogenomics·2022· 9 citedOpen Access
Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells
Nature Communications·2022· 97 citedOpen Access
Strong Association of Combined Genetic Deficiencies in the Classical Complement Pathway With Risk of Systemic Lupus Erythematosus and Primary Sjögren's Syndrome
Arthritis & Rheumatology·2022· 30 citedOpen Access
POS0632 EXPRESSION OF PD-1 AND PD-L1 IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WITH PRE-EXISTING RHEUMATOID ARTHRITIS – A POSSIBLE ASSOCIATION WITH HIGH RHEUMATOID ARTHRITIS DISEASE ACTIVITY
Annals of the Rheumatic Diseases·2022Open Access
POS0519 RELATIONSHIP BETWEEN DISEASE ACTIVITY AND MAJOR ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TOFACITINIB OR TNF INHIBITORS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
Annals of the Rheumatic Diseases·2022· 12 citedOpen Access
POS0637 SAFETY OF b/tsDMARDs FOR RA AS USED IN CLINICAL PRACTICE - RESULTS FROM THE LAST DECADE OF THE ARTIS PROGRAM
Annals of the Rheumatic Diseases·2022· 2 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Johan Askling(26), Nils Feltelius(17), Lars Klareskog(17), Carin Backlin(11), Christer Sundström(11), Karin E. Smedby(8), Helena Forsblad‐d’Elia(8), Solbritt Rantapää‐Dahlqvist(7), Gunilla Enblad(7), L. Jacobsson(6), Ronald van Vollenhoven(6), Merete Lund Hetland(6), Elisabet Lindqvist(6), Richard Rosenquist(5), Gunnel Nordmark(5), Roland Jonsson(5), L Cöster(5), Tore Saxne(5), Marie Wahren‐Herlenius(5), Thomas Frisell(5)